Contact Us
TEL: +86-0571-88334626
E-mail: sales@tacon-china.com.cn
Home > News > Content
Current Status Of Biopharmaceutical Industry
Jun 02, 2018

The market situation

As an important part of the national economy, the pharmaceutical industry is closely related to the vital interests of the people, such as their health and quality of life. Since China's reform and opening up, Chinese pharmaceutical industry has maintained rapid growth rate, 1978-2010, medicine annual industrial output growth is above 15%, the scale expands unceasingly, improve economic running quality and benefits. China has become the world's largest producer of pharmaceutical preparations.

The results of biotechnology, combined with the principles and methods of microbiology, chemistry, biochemistry and pharmacy, have formed one of the important sub-industries in the pharmaceutical industry.

The state has increased its support for biotechnology innovation and the development of the biotechnology industry, thus maintaining the rapid development momentum of China's biopharmaceutical industry. According to the data, the annual compound growth rate of China's biopharmaceutical industry from 2003 to 2010 was 21.52%. In 2010, the industry's production and sales volume exceeded 100 billion yuan, with a year-on-year growth rate of more than 40%.

It is believed that a number of gene therapy programs and drugs will enter the application stage in the next decade. China's research and development and industrialization capacity of biological drugs will also be greatly improved, forming a new pattern of drugs featuring chemical drugs, traditional Chinese medicine and biological drugs. China will for cancer, heart disease, high blood pressure, diabetes, neurological diseases such as serious illness, made 200 new drug certificate, the development of nearly 200 kinds of biological medicine, nearly 400 biological medicine into the clinical trials, the high-speed development of Chinese bio-pharmaceutical era has arrived.

In 2011, biopharmaceutical sales reached us $160 billion, accounting for 19% of the global pharmaceutical market. It is expected that by 2020, biopharmaceuticals will account for more than one-third of global drug sales. The annual output value of China's pharmaceutical manufacturing industry has exceeded 1.2 trillion yuan, and the annual export growth rate has been stable at 25-30%. Among them, chemical API is an important industry that represents the international competitiveness of China's pharmaceutical industry. Its annual output value accounts for nearly half of the total national medical output value, and its export proportion exceeds 60%. The global market for biosimilars will grow from $2.43 million in 2010 to $3.7 billion in 2015, equivalent to a $51 billion loss in sales of 30 branded drugs. In 2015, annual sales of biosimilars in our country, from 274.8 billion yuan in 2011, rose to 447.8 billion yuan, an average annual compound growth rate of about 15%, and will always accounts for the biological medicine to about 62% of total sales. Sales of patented drugs are expected to continue to grow by more than 25 per cent between 2012 and 2016. With some big biological drug patents expire, 2010-2017, $150 billion worth of drugs will lose patent protection, this will push generics market from $123.85 billion in 2010 to $2017 in 231 billion. [1]

Technology development

The biotech camp is huge and growing fast. Half of the world's pharmaceuticals are biosynthesised, especially when it comes to synthetic drugs with complex molecular structures.

Half a century development of pharmaceutical analysis system and various kinds of microbial transformation in the application of a series of breakthrough in drug development to the pharmaceutical industry has created a huge medical value and economic benefits. The microbe pharmaceutical industry is characterized by the use of certain microorganisms in a "pure seed state", that is, not only "seed" but also only one species, such as other species come in for hybrid bacteria. For a fixed product, there must be the most suitable "rice" - culture medium for it to grow. The composition of the culture medium cannot be changed at will. A strain is in the same fermentation medium, and the fermented product is completely different because there are only a few or more ingredients. For example, Streptomyces aureus can form aureomycin in chlorinated medium, and tetracycline can be produced in the absence of chlorides or by adding substances in the medium that inhibit chlorination. Drug producing bacteria must be prepared by seed expansion when they are put into fermentation tank production. From the preserved seed inclined plane to the flask culture, the long flask seeds are connected to the large amount of seed tank, and after the growth can be connected to the fermentation tank culture. Different fermentation scales also have different fermentation tanks, such as 10 tons, 30 tons, 50 tons, 100 tons, and even larger ones. It's like a pan of different sizes that we use for cooking.